FrancophonIA/ELRC3.0 huggingface dataset:
English: This subgroup comprised 21% (253/1202) of the FL ITT population and experienced 16.3% (40/245) of the PFS events.
Danish: Denne subgruppe omfattede 21% (253/1202) af follikulært lymfom intention-to-treat-populationen og udgjorde 16,3 % (40/245) af progressionsfri overlevelse tilfældene.Desuden var de eksplorative subgruppe analyser af progressionsfri overlevelse på tværs af kemoterapi behandlinger (bendamustin, CHOP og CVP) i overensstemmelse med resultaterne observeret i Gazyvaro plus kemoterapi populationen.
English: Patients must not receive further Gazyvaro infusions if they experience: · acute life-threatening respiratory symptoms, · a Grade 4 (i.e. life threatening) IRR or, · a second occurrence of a Grade 3 (prolonged/recurrent) IRR (after resuming the first infusion or during a subsequent infusion).
Danish: • gentagelse af en grad 3infusionsrelateret reaktion (forlænget/recidiverende) (efter genoptagelse af første infusion eller under en efterfølgende infusion).
English: Contents of the pack and other information What Gazyvaro contains · The active substance is obinutuzumab: 1,000 mg/40 mL per vial corresponding to a concentration before dilution of 25 mg/mL.
Danish: • Det aktive indholdsstof er obinutuzumab: 1000 mg/40 ml per hætteglas svarende til en koncentration på 25 mg/ml inden fortynding.
English: If no IRR occurred during the previous infusion, when the final infusion rate was 100 mg/hr or faster, infusions can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Danish: Hvis ingen infusionsrelateret reaktion opstod under den forudgående infusion, da slut-infusionshastigheden var 100mg/time eller højere, kan infusion startes ved 100 mg/time og øges i trin af 100 mg/time hver 30. minut til maksimalt 400 mg/time.
English: How Gazyvaro works
Danish: Hvordan virker Gazyvaro?
English: If no IRR or if an IRR Grade 1 occurred during the previous infusion when the final infusion rate was 100 mg/hr or faster, infusions can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Danish: Hvis ingen infusionsrelateret reaktion eller en infusionsrelateret reaktion af grad 1 opstod under den forudgående infusion, da slut-infusionshastighed var 100 mg/time eller højere, kan infusion startes ved 100 mg/time og øges i trin af 100 mg/time hver 30. minut til maksimalt 400 mg/time.
English: For instructions on dilution of Gazyvaro before administration, see section 6.6.
Danish: 6.6 for vejledning i fortynding af Gazyvaro inden brug.
English: Cough, oropharyngeal pain
Danish: Hoste, orofaryngeal smerte
English: The incidence of neutropenia was higher in the Gazyvaro plus chlorambucil arm (41%) compared to the rituximab plus chlorambucil arm with the neutropenia resolving spontaneously or with use of granulocyte-colony stimulating factors.
Danish: Incidensen af neutropeni var højere i Gazyvaro plus chlorambucil-armen (41%) end i rituximab plus chlorambucil-armen.
English: All subsequent infusions for CLL and FL
Danish: Alle efterfølgende infusioner gælder for kronisk lymfatisk leukæmi og follikulært lymfom
English: White blood cell count decreased, neutrophil count decreased, weight increased
Danish: Fald i leukocytter, fald i neutrofilocytter, vægtøgning
English: Vaccination with live virus vaccines is not recommended during treatment and until B-cell recovery because of the immunosuppressive effect of obinutuzumab (see section 4.4).
Danish: På grund af obinutuzumabs immunsupprimerende effekt frarådes vaccination med levende virusvacciner under behandling og indtil B-celleniveauet er normaliseret (se pkt.
English: Figure 2 Kaplan-Meier curve of OS from Stage 1a in patients with CLL (Study BO21004/CLL11)
Danish: Kaplan-Meier-kurve over samlet overlevelse fra stadie 1a hos patienter med kronisk lymfatisk leukæmi (studie BO21004/CLL11)
English: Figure 6 Kaplan-Meier curve of IRC-assessed PFS in patients with FL # (Study GAO4753g/GADOLIN)
Danish: Kaplan-Meier-kurve over progressionsfri overlevelse, vurderet af en uafhængig komité, hos patienter med follikulært lymfom# (GAO4753g /GADOLIN-studiet)
English: Figure 1 Kaplan-Meier curve of Investigator assessed PFS from Stage 1a in patients with CLL (Study BO21004/CLL11)
Danish: Kaplan-Meier-kurve over investigator-vurderet progressionsfri overlevelse fra stadie 1a hos patienter med kronisk lymfatisk leukæmi (studie BO21004/CLL11)
English: Table 5 Follicular lymphoma: Standard infusion rate in the absence of IRRs /hypersensitivity and recommendations in case an IRR occurred with previous infusion
Danish: Tabel 5 Follikulært lymfom: Standard-infusionshastighed, hvis der ikke ses infusionsrelaterede reaktioner/overfølsomhed, samt anbefalinger i tilfælde af infusionsrelaterede reaktioner opstået under den forudgående infusion
English: Cycles 2-6
Danish: Behandlingsserie 2 -6
English: Figure 3 Kaplan-Meier curve of investigator assessed PFS from Stage 2 in patients with CLL (Study BO21004/CLL11)
Danish: Kaplan-Meier-kurve over investigator-vurderet progressionsfri overlevelse fra stadie 2 hos patienter med kronisk lymfatisk leukæmi (studie BO21004/CLL11)
English: Atrial fibrillation, cardiac failure Atrial fibrillation, cardiac failure,
Danish: Atrieflimren, hjertesvigt
English: Figure 4 Kaplan-Meier curve of OS from Stage 2 in patients with CLL (Study BO21004/CLL11)
Danish: Kaplan-Meier-kurve over samlet overlevelse fra stadie 2 hos patienter med kronisk lymfatisk leukæmi (studie BO21004/CLL11)
English: Table 4 Chronic lymphocytic leukaemia: Standard infusion rate in the absence of IRRs/hypersensitivity and recommendations in case an IRR occurred with previous infusion
Danish: Tabel 4 Kronisk lymfatisk leukæmi: Standard-infusionshastighed,hvis der ikke ses infusionsrelaterede reaktioner/overfølsomhed, samt anbefalinger i tilfælde af infusionsrelaterede reaktioner opstået under den forudgående infusion
English: Grades 3-5† Gazyvaro + chemotherapy* (CLL, iNHL) followed by Gazyvaro maintenance (iNHL)
Danish: Gazyvaro + kemoterapi* (kronisk lymfatisk leukæmi, indolent non-Hodgkin lymfom)efterfulgt af Gazyvarovedligeholdelsesbehandling (indolent non-Hodgkin lymfom)
English: These trials investigated Gazyvaro in combination with chlorambucil for CLL and with bendamustine, CHOP or CVP followed by Gazyvaro maintenance therapy for iNHL.
Danish: I disse studier blev Gazyvaro undersøgt i kombination med chlorambucil hos patienter med kronisk lymfatisk leukæmi og med bendamustin, CHOP eller CVP efterfulgt af Gazyvaro vedligeholdelsesbehandling hos patienter med indolent non-Hodgkin lymfom.. BO21223/GALLIUM og GAO4753g/GADOLINstudierne rekrutterede patienter med indolent non-Hodgkin lymfom herunder follikulært lymfom.
English: Musculoskeletal chest pain, pain in extremity, bone pain
Danish: Muskuloskeletale brystsmerter, ekstremitetssmerter, knoglesmerter
English: IRC: Independent Review Committee; PFS: progression-free survival; HR: Hazard Ratio; CI: Confidence Intervals, NR = Not Reached # Patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen *Stratification factors for analysis were refractory type (rituximab monotherapy vs. rituximab + chemotherapy) and prior therapies (≤ 2 vs > 2).
Danish: Patienter med follikulært lymfom, som ikke responderede eller som fik sygdomsprogression under eller op til 6 måneder efter behandling med rituximab eller en behandling indeholdende rituximab *Stratificeringsfaktorer for analysen var refraktær type (rituximab monoterapi versus rituximab + kemoterapi) og antal tidligere behandlinger (≤ 2 versus >2).
English: IRC-assessed PFS (PFS-IRC) Number (%) of patients with event HR [95% CI] p-value (Log-Rank test, stratified*) Time to next anti-lymphoma therapy# Number (%) of patients with event HR [95% CI] p-value (Log-Rank test, stratified*) Overall Survival
Danish: Primært endepunkt Progressionsfri overlevelse vurderet af investigator Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) 3-årig estimat af progressionsfri overlevelse (95% konfidensinterval) Vigtige endepunkter Progressionsfri overlevelse vurderet af en uafhængig komité Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p-værdi (stratificeret log-rank test*) Tid indtil næste anti-lymfom behandling Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) Samlet overlevelse# Antal (%) patienter med hændelse Hazard ratio (95% konfidensinterval) p- værdi (stratificeret log-rank test*) Samlet responsrate** ved endt induktionsbehandling‡ (investigatorvurderet, CT) Respondere
English: Figure 8 IRC-assessed PFS by patient subgroup in FL *# (Study GAO4753g/GADOLIN)
Danish: Progressionsfri overlevelse, vurderet af en uafhængig komité, i patient-sub-grupper hos patienter med follikulært lymfom*# (GAO4753g /GADOLIN-studiet)
English: Musculoskeletal and connective tissue disorders Very common
Danish: Blod og lymfesystem Meget almindelig
English: HR (95% CI)
Danish: Hazard ratio (95%
English: Premedication
Danish: Dosering
English: If the patient experienced an IRR during the previous infusion administer at 50 mg/hr.
Danish: Hvis patienten har oplevet en infusionsrelateret reaktion i den foregående infusion, start med administration på 50 mg/time.
English: GAO4753g/GADOLIN) that occurred at a higher incidence (difference of ≥ 2%) compared to the relevant comparator arm in at least one pivotal study in: · Patients with CLL receiving Gazyvaro plus chlorambucil compared with chlorambucil alone or rituximab plus chlorambucil (study BO21004/CLL11) · Patients with previously untreated iNHL receiving Gazyvaro plus chemotherapy (bendamustine, CHOP, CVP) followed by Gazyvaro maintenance in patients achieving a response, compared to rituximab plus chemotherapy followed by rituximab maintenance in patients achieving a response (study BO21223/GALLIUM) · Patients with iNHL who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen receiving Gazyvaro plus bendamustine, followed by Gazyvaro maintenance in some patients, compared to bendamustine alone (study GAO4753g/GADOLIN) The incidences presented in Table 6 (all grades and Grades 3-5) are the highest incidence of that ADR reported from any of the three studies.
Danish: • patienter med tidligere ubehandlet indolent non-Hodkin lymfom, der fik Gazyvaro plus kemoterapi (bendamustin, CHOP, CVP) efterfulgt af Gazyvaro vedligeholdelsesbehandling hos patienter, der opnåede et respons, sammenlignet med rituximab plus kemoterapi efterfulgt af rituximab vedligeholdelsesbehandling hos patienter, der opnåede et respons (studie BO21223/GALLIUM)
English: Your doctor may decide to stop treatment with Gazyvaro if you have a severe infusion related reaction.
Danish: Hvis reaktionen har været meget kraftig, kan lægen vælge helt at stoppe behandlingen med Gazyvaro.
English: In a phase III, open label, multicentre, randomised clinical study (GAO4753g/GADOLIN), 396 patients with iNHL who had no response during treatment or who progressed within 6 months following the last dose of rituximab or a rituximab-containing regimen (including rituximab monotherapy as part of induction or maintenance treatment) were evaluated.
Danish: • GAO4753g/GADOLIN (N=392): Patienter med indolent non-Hodgkin lymfom (81% af patienterne havde follikulært lymfom), som ikke havde responderet på eller som havde progredieret under eller op til 6 måneder efter behandling med rituximab eller et rituximabindeholdende behandlingsregime.
English: Patients (CLL) with both CIRS > 6 and CrCl < 70 mL/min are more at risk of infections, including severe infections (see section 4.8).
Danish: Patienter med kronisk lymfatisk leukæmi, med en co-morbiditetsscore >6 på CIRSskalaen (Cumulative Illness Rating Scale) samt CrCl <70 ml/min har højere risiko for infektioner, inklusive svære infektioner (se pkt.
English: Posology
Danish: Nedsat nyrefunition
English: 2 Bendamustine is given intravenously on Days 1 and 2 of all treatment cycles (Cycles 1-6) at 90 mg/m2/day; CHOP and CVP according to standard regimens
Danish: 2Bendamustin gives intravenøst på 1. og 2. behandlingsdag i alle behandlingsserier (serie 1-6) i en dosis på 90
English: Oral analgesic/anti-pyretic2 At least 30 minutes before Gazyvaro infusion
Danish: Intravenøst kortikosteroid4 Afsluttet mindst 1 time inden infusion af
English: Hazard ratio (95% CI) p-value (Log-Rank test, stratifiedb) Overall survival
Danish: Hazard ratio (95% konfidensinterval)
English: Upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose (see Tables 4 and 5).
Danish: Når symptomerne er forsvundet, kan infusionen genoptages ved maksimalt halvdelen af den tidligere infusionshastighed (af den infusionshastighed, der anvendtes på det tidspunkt den infusionsrelaterede reaktion opstod).
English: In patients who received the recommended measures for prevention of IRRs as described in section 4.2, a decreased incidence of IRRs of all Grades was observed.
Danish: 4.2, blev der observeret en lavere incidens af infusionsrelaterede reaktioner af alle grader.
English: The rate of infusion can be escalated in increments up to 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Danish: Infusionshastigheden kan øges i intervaller på op til 50 mg/time hver 30. minut til maksimalt 400 mg/ time.
English: Laboratory abnormalities
Danish: Laboratorieafgivelser
English: The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Danish: Infusionshastigheden kan øges i trin af 50 mg/time hver 30. minut til maksimalt 400 mg/time.
English: Date of latest renewal:
Danish: En opdateret RMP skal fremsendes:
English: Neoplasms benign, malignant and unspecified (incl cysts and polyps) Common
Danish: cyster og polypper) Almindelig
English: The studies BO21223/GALLIUM and GAO4753g/GADOLIN enrolled patients with iNHL including FL.
Danish: I et, ublindet, randomiseret klinisk fase III-multicenterstudie (GAO4753g /GADOLIN), blev 396 patienter med indolent non-Hodgkin lymfom undersøgt.
English: In all cases the doses are adjusted to obtain haemoglobin levels that remain within the recommended range.
Danish: I samtlige tilfælde tilpasses doserne, således at der opnås hæmoglobinniveauer, der forbliver inden for det anbefalede område.
English: Nespo exists in various strengths, from 10 to 500 micrograms per millilitre.
Danish: Nespo findes i forskellige styrker fra 10 til 500 mikrogram/ml.
English: The Committee recommended that Nespo be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Nespo.
English: Lower doses may be necessary for children with kidney failure aged 10 years or below.
Danish: Lavere doser kan være påkrævet til børn med nyresvigt i aldersgruppen op til 10 år.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nespo to Dompé Biotec S.p.A. on 8 June 2001.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Nespo til Dompé Biotec S.p.A.
English: Nespo treatment should be initiated by a doctor who has experience in treating either of the two types of anaemia mentioned above.
Danish: Behandlingen med Nespo bør igangsættes af en læge med erfaring i behandling af de to ovennævnte former for anæmi.
English: This summary was last updated in 09-2007.©EMEA 2007
Danish: Dette sammendrag blev sidst ajourført i 09-2007.
English: Darbepoetin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce darbepoetin alfa.
Danish: Darbepoetin alfa fremstilles ved rekombinant DNA-teknik: Det produceres af en celle, der har fået indsat et gen (DNA), som gør cellen i stand til at producere darbepoetin alfa.
English: Doses and dose frequency (how often Nespo is given) are adjusted depending on the response.
Danish: Dosering og dosisintervaller (hvor ofte Nespo anvendes) bliver tilpasset efter, hvordan behandlingen virker.
English: Nespo works by stimulating the production of red blood cells in the same way as natural erythropoietin.
Danish: Nespo virker ved at stimulere produktionen af røde blodlegemer på samme måde som naturligt erythropoietin.
English: Nespo is used to treat anaemia (fewer red blood cells in the blood than normal) in two groups of patients:
Danish: Nespo anvendes til behandling af anæmi (færre røde blodlegemer i blodet end normalt) hos to grupper
English: The dose used depends on why Nespo is used, varying from 0.45 micrograms per kilogram every week (or 0.75 micrograms/kg every other week) in adults and children with kidney failure aged 11 years or older, to 6.75 micrograms/kg every three weeks in cancer patients.
Danish: Den anvendte dosis afhænger af, hvad Nespo anvendes til, og varierer fra 0,45 mikrogram/kg ugentligt (eller 0,75 mikrogram/kg hver anden uge) hos voksne og børn med nyresvigt, i aldersgruppen 11 år eller ældre, til 6,75 mikrogram/kg hver tredje uge hos kræftpatienter.
English: • adult patients with certain types of cancer who are receiving chemotherapy (the medicines used to treat cancer), when the chemotherapy stops the bone marrow producing enough blood cells.
Danish: • voksne patienter, som har visse former for kræft og er i behandling med kemoterapi (kræftbekæmpende medicin), når kemoterapien bevirker, at knoglemarven ikke producerer tilstrækkeligt med blodceller.
English: • adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,
Danish: • voksne og børn i aldersgruppen 1 år eller ældre, der lider af anæmi, som skyldes kronisk nyresvigt, hvor kroppen producerer for lidt af det naturlige hormon erythropoietin
English: The main measure of effectiveness in patients with kidney disease was the increase in haemoglobin.
Danish: Det vigtigste mål for virkningen hos patienter med nyresygdom var stigningen i hæmoglobin.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Nespo's benefits are greater than its risks for the treatment of anaemia associated with chronic renal failure in adults and paediatric patients, and of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Danish: Udvalget for humanmedicinske lægemidler (CHMP) besluttede, at fordelene ved Nespo var større end risiciene til behandling af anæmi i forbindelse med kronisk nyresvigt hos voksne og pædiatriske patienter og symptomatisk anæmi hos voksne kræftpatienter med ikke-myeloid malignitet i kemoterapi.
English: How has Nespo been studied?
Danish: Hvordan blev Nespo undersøgt?
English: Nespo has also been studied in 124 children with long-term kidney disease to check that it is absorbed in the same way as in adults.
Danish: Nespo er også blevet undersøgt hos 124 børn med langvarig nyresygdom for at kontrollere, om det
English: Nespo should not be used in people who may be hypersensitive (allergic) to darbepoetin alfa or any of the other ingredients, or in patients who have poorly controlled high blood pressure.
Danish: Nespo må ikke anvendes af patienter, der kan være overfølsomme (allergiske) over for darbepoetin alfa eller andre af indholdsstofferne, eller af patienter med ikke-velkontrolleret forhøjet blodtryk.
English: Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Danish: Hæmoglobin er det protein i de røde blodceller, der transporterer ilt rundt i
English: The effectiveness of Nespo has been studied in patients with long-term kidney disease, where it was compared with recombinant human erythropoietin in four studies involving over 1,200 patients, and in patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma, where it was compared with placebo (a dummy treatment) in two studies involving 669 patients.
Danish: Virkningen af Nespo er undersøgt hos patienter med langvarig nyresygdom (hvor Nespo blev sammenlignet med rekombinant humant erythropoietin i fire undersøgelser med flere end 1 200 patienter) og hos patienter i kemoterapi for kræftformer som lungekræft, myelom eller lymfom, hvor Nespo blev sammenlignet med placebo (virkningsløs behandling) i to undersøgelser med 669 patienter.
English: A lack of natural erythropoietin is also one of the causes of anaemia in patients receiving chemotherapy.
Danish: Mangel på naturligt erythropoietin er ligeledes medvirkende til anæmien hos patienter i kemoterapi.
English: Nespo is supplied ready for use in a pre-filled syringe or pre-filled pen, which can be used by the patient or their carer.
Danish: Nespo leveres klar til brug i fyldte sprøjter eller i fyldte injektionspenne, som kan anvendes af patienten selv eller plejepersonalet.
English: The most common side effects with Nespo (seen in between 1 and 10 patients in 100) are headache, hypertension (high blood pressure), thrombosis (blood clots), injection site pain, arthralgia (joint pain) and peripheral oedema (fluid retention).
Danish: De hyppigste bivirkninger af Nespo (som kunne observeres hos mellem 1 og 10 patienter ud af 100) er hovedpine, for højt blodtryk, trombose (blodpropper), smerte på injektionsstedet, ledsmerter og væskeansamling i lemmerne.
English: The marketing authorisation was renewed on 8 June 2006.
Danish: den 8. juni 2001.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NESPO EPAR summary for the public
Danish: EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) NESPO
English: The types of cancer where Nespo can be used are ‘non-myeloid' (do not affect the bone marrow).
Danish: De kræftformer, hvor Nespo kan anvendes, er ikke-myeloide
English: How does Nespo work?
Danish: Hvordan virker Nespo?
English: Nespo was as effective as human recombinant erythropoietin at increasing the haemoglobin levels in patients with kidney disease, and at keeping these levels maintained after they had been improved, whether given as an intravenous or subcutaneous injection.
Danish: Nespo var lige så effektivt som rekombinant human erythropoietin til at øge hæmoglobinniveauet hos patienter med nyresygdom og til at fastholde dette niveau, efter at det var bedret.
English: In cancer patients receiving chemotherapy, fewer patients treated with Nespo needed a blood transfusion compared with those given placebo.
Danish: Hos kræftpatienter i kemoterapi var blodtransfusion nødvendig hos færre patienter i Nespo-gruppen end i placebogruppen.
English: For the full list of all side effects reported with Nespo, see the Package Leaflet.
Danish: Den fuldstændige liste over de indberettede bivirkninger ved Nespo
English: A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
Danish: Hormonet erythropoietin stimulerer knoglemarven til at producere flere røde blodlegemer.
English: Darbepoetin alfa, the active substance in Nespo, acts exactly like the natural erythropoietin made by the body, but it is very slight different in its structure, and this means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin.
Danish: Darbepoetin alfa, det aktive stof i Nespo, virker fuldstændig som det naturlige erythropoietin, der produceres af kroppen, men har ikke helt samme opbygning.
English: Nespo is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen.
Danish: Nespo er en injektionsvæske, der leveres i hætteglas, fyldte sprøjter og fyldte injektionspenne.
English: What is the risk associated with Nespo?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Nespo?
English: In patients with long-term kidney failure, the main cause of their anaemia is a lack of natural erythropoietin.
Danish: Mangel på naturligt erythropoietin er hovedårsagen til anæmien hos patienter med langvarigt nyresvigt.